Frequency is how often a label has an administration; timing is when within the day or week, and how far apart doses must be. Both are written into product labels, and both differ between products. This guide collects what a set of US and Singapore labels print, shows how half-life is described next to those patterns, and stops there. It is not a schedule for any reader, and a pattern in one label does not transfer to another product. For on and off periods across weeks and months, see cycling basics.
Guide
Dosing Frequency and Timing: Daily, Weekly, Twice-Weekly and As-Needed Patterns in Labels
How approved labels word daily, weekly, twice-weekly and as-needed patterns, how half-life is described next to them, and what they print on day changes.
By Sam, MBA. Human-researched and AI-assisted with full editorial review. Last reviewed October 2026.
Four patterns, with label examples
Daily. The EGRIFTA SV label, for HIV-infected adult patients with lipodystrophy, gives 1.4 mg injected subcutaneously once daily.[1] The EGRIFTA WR label, for a different vial formulation, gives 1.28 mg once daily and states that the two products are not substitutable.[2]
Weekly. The Ozempic, Wegovy, Zepbound and Mounjaro labels all specify once-weekly subcutaneous injection.[3][4][5][6] Weekly labels also say when in the week: Ozempic and Wegovy state the same day each week, at any time of the day, with or without meals.[3][4] The Wegovy label adds that the time of day and the injection site can be changed without the need for a dosage modification.[4]
Twice weekly. The Zadaxin information gives 1.6 mg subcutaneously twice a week for 6 to 12 months in chronic hepatitis B, and twice a week for 12 months in chronic hepatitis C when used with interferon.[7] The product information does not state a minimum spacing between the two weekly doses. The Novarel label lists several regimens in USP Units, including three times weekly and every second day, and one regimen of three times a week for three weeks followed by the same dose twice a week for three weeks, listed for selected cases of hypogonadotropic hypogonadism in males.[9] The label describes these as regimens advocated by various authorities.[9]
As needed, with caps. The Vyleesi label, for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), gives 1.75 mg subcutaneously as needed at least 45 minutes before anticipated sexual activity, and says not to administer more than one dose within 24 hours.[8] It also states that more than 8 doses per month is not recommended, and that the optimal window for administration has not been fully characterized.[8] The cap is a ceiling, not a schedule.
Summary table
| Pattern | Label example | Frequency as printed |
|---|---|---|
| Daily | EGRIFTA SV, EGRIFTA WR (HIV-infected adult patients with lipodystrophy) | Once daily [1][2] |
| Weekly | Ozempic, Wegovy, Zepbound, Mounjaro | Once weekly [3][4][5][6] |
| Twice weekly | Zadaxin | Twice a week for 6 to 12 months in chronic hepatitis B [7] |
| Three times weekly then twice weekly | Novarel (one listed regimen) | Three times a week for three weeks, then twice a week for three weeks (label regimen for selected cases of hypogonadotropic hypogonadism in males) [9] |
| As needed | Vyleesi (premenopausal women with HSDD) | Not more than one dose in 24 hours; more than 8 doses per month not recommended [8] |
Half-life next to the schedule
Half-life is the time for the amount in the body to fall by half. Labels print it in their pharmacokinetic sections. The values below are the labels' own and each is for that product only.
- Tesamorelin: mean elimination half-life of 8 minutes after a single 1.4 mg EGRIFTA SV dose,[1] and 11 minutes after a single 1.28 mg EGRIFTA WR dose.[2] Both labels give a once-daily schedule.
- Semaglutide: the Ozempic label refers to a long half-life of approximately 1 week.[3] One week is 168 hours (arithmetic), which is the value the half-life calculator loads for semaglutide.[3]
- Tirzepatide: the Mounjaro label gives an elimination half-life of approximately 5 days, enabling once-weekly dosing.[6] The Zepbound label gives approximately 5 to 6 days in its pharmacokinetics section.[5]
- Bremelanotide: the Vyleesi label gives a mean terminal half-life of approximately 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous administration.[8]
- CJC-1295 with DAC: the abstract of a trial in healthy men describes the albumin-binding analogue as having a half-life of 8 days and studied the effect 1 week after a single injection.[10] The abstract describes a research analogue and not an approved product.
Reading these side by side shows that the label schedule and the half-life are stated separately. Only the Mounjaro label links them in words, by saying the half-life enables once-weekly dosing.[6] The Wegovy label states that semaglutide has an elimination half-life of approximately 1 week and will be present in the circulation for about 5 to 7 weeks after the last injectable dose of 2.4 mg or 7.2 mg.[4] Half-life describes the product's decline. The label's regimen is set by the label's own studies. After one half-life half remains, after two a quarter remains, and the calculator shows that decay as arithmetic.
Timing rules labels print
Changing the day of a weekly dose. The wording is product-specific.
- Ozempic: the day can be changed if necessary as long as the time between two doses is at least 2 days (more than 48 hours).[3]
- Wegovy: the patient information says the day can be changed as long as the last dose was given 2 or more days before.[4]
- Zepbound and Mounjaro: the day can be changed if necessary as long as the time between the two doses is at least 3 days (72 hours).[5][6]
Spacing and caps. Vyleesi sets a 24-hour limit and a monthly limit, as above.[8] The EGRIFTA dosing sections read for this guide give once daily without a further interval rule.[1][2]
Missed doses. Each weekly label has its own window, and Wegovy also has a rule for two or more consecutive missed doses. They are set out in titration schedules explained.
How the site shows frequency
The dose table has a frequency column that repeats the label's words, and the titration table repeats it per step. A cycle row is a separate figure with its own source; the cycles page lists them. Where no source states a frequency, the cell is blank. The protocol schedule guide shows how to turn a cited frequency into a calendar.
Related
How to read a dosing protocol, the half-life calculator, the master dosage chart, and syringe units.
References
- EGRIFTA SV (tesamorelin) US label, DailyMed
- EGRIFTA WR (tesamorelin) US prescribing information, FDA, revised March 2025
- Ozempic (semaglutide) US label, DailyMed
- Wegovy injection US label, DailyMed
- Zepbound (tirzepatide) US label, DailyMed
- Mounjaro (tirzepatide) US label, DailyMed
- Zadaxin (thymalfasin) product information, Singapore HSA (SIN07483P)
- Vyleesi (bremelanotide) US label, DailyMed
- Novarel (chorionic gonadotropin) US label, DailyMed
- Ionescu and Frohman, J Clin Endocrinol Metab 2006: CJC-1295 and GH pulsatility (PMID 17018654)
More guides
- 6 min readPeptide Beginner’s Guide: Vials, Supplies, Evidence and Safety BasicsA plain-language orientation to peptide vials, reconstitution, storage, syringes, certificates of analysis and how to judge the evidence behind a protocol.
- 6 min readHow to Reconstitute Peptides: Steps, Concentration Math and Label ExamplesStep-by-step reconstitution of a lyophilised peptide vial, with the concentration formula and two FDA label examples of diluent and discard times.
- 6 min readPeptide Storage Guide: Lyophilised Vials, Reconstituted Solutions and Beyond-Use DatesHow manufacturers and FDA labels say to store lyophilised and reconstituted peptides, why the advice differs by product, and how to date a vial.
- 5 min readSyringe Units Guide: U-100 Markings, mL and mg Conversion ExplainedHow U-100 insulin syringe units relate to mL and to mg of peptide, with the conversion formulas, a table, and the unit-versus-volume errors to avoid.
- 7 min readSubcutaneous Injection Technique: Published Guidance on Sites, Needles, Angle and DisposalEducational summary of published subcutaneous injection technique from FDA labels, MedlinePlus, NHS guidance and a diabetes injection consensus.
- 5 min readBAC Water (Bacteriostatic Water): What It Is, Label Facts and Handling LimitsWhat bacteriostatic water contains, what its FDA label says about use, neonates, storage and endotoxin limits, and the 28-day multi-dose rule.
- 6 min readHow to Read a Peptide COA: Identity, Purity, Content, Endotoxin and Lot ChecksA field-by-field walkthrough of a real peptide certificate of analysis: what purity, content, identity, endotoxin and lot lines do and do not tell you.
- 7 min readPeptide Stacking Basics: What a Stack Is and What the Evidence Actually ShowsWhat stacks and blends are, the five evidence levels behind combining peptides, and why most published stacks are community-reported.
- 7 min readPeptide Cycling Basics: On/Off Schedules, Half-Life and What Is Actually DocumentedWhat peptide cycles are, how approved labels handle duration and breaks, the desensitization evidence, and why most cycle lengths are community-reported.
- 6 min readBuilding a Protocol Schedule: Using the Calculators, Planner, Timer and Calendar FileStep by step through the site tools: concentration, syringe units, titration table, cycle totals, vial planner, storage timer, print and calendar file.
- 6 min readHow to Read a Dosing Protocol: Ranges, Units, Routes and Evidence GradesHow a protocol page is built: dose range versus amount per draw, units, route, frequency, population, and what evidence grades A to E mean.
- 6 min readTitration Schedules Explained: Why Labels Step Up and How to Read a Titration TableWhat titration means, how the Wegovy, Ozempic, Zepbound and Mounjaro labels word step intervals, maximums and missed doses, and how to read the table.